VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

ADS-MVA vaccine
Vaccine Information
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: None
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: S protein(Chen et al., 2005)
  • S protein gene of SARS-CoV gene engineering:
    • Type: Recombinant vector construction
    • Detailed Gene Information: Click Here.
  • Vector: live-attenuated modified vaccinia virus Ankara (MVA) (Chen et al., 2005)
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: Recombinant live-attenuated modified vaccinia virus Ankara (MVA) had full-length SARS-CoV envelope Spike (S) glycoprotein gene was introduced into the deletion III region of the MVA genome.
    (Chen et al., 2005)
Host Response

Mouse Response

  • Host Strain: Balb/c (Chen et al., 2005)
  • Vaccination Protocol: immunized intramuscular injection twice with a 3-week interval. Two mice were given 2 × 106 TCID50 of the vaccine, and six mice received 2 × 107 TCID50.(Chen et al., 2005)
  • Immune Response: testing hosts generated high levels of neutralizing antibodies (Chen et al., 2005)

Rabbit Response

  • Vaccination Protocol: immunized intramuscular injection twice with a 3-week interval (Chen et al., 2005)
  • Immune Response: testing hosts generated high levels of neutralizing antibodies (Chen et al., 2005)

Ferret Response

  • Vaccination Protocol: Each ferret was immunized with rMVA-S (ferrets 7 to 9), n day 0 with a dose of 1e8 PFU of the corresponding virus per ferret by intraperitoneal and subcutaneous routes, and a booster immunization was given on day 14 with the same regimen.(Weingartl et al., 2004)
  • Immune Response: Neutralizing activity was detected in sera along with a corresponding immunoglobin G titer collected from all three ferrets 7 days after booster immunization with rMVA-S virus, while the titer declined to undetectable level 14 days after the booster (Weingartl et al., 2004).
  • Side Effects: Ferrets immunized with rMVA-S (particularly ferret 9) developed severe periportal and panlobular mononuclear hepatitis in contrast to only mild periportal mononuclear hepatitis was observed in control ferrets (Weingartl et al., 2004) .
  • Challenge Protocol: Ferrets were challenged with 1e6 PFU of the SARS-CoV Tor2 isolate by the intranasal route(Weingartl et al., 2004).
  • Description: Study shows correlation with liver damage but does not definitely proof it is caused as SARS-CoV in ferrets also damage liver.(Weingartl et al., 2004)

Macaque Response

  • Vaccination Protocol: immunized intramuscular injection twice with a 4-week interval. 1 × 108 TCID50 for the first immunization and a dose of 3 × 108 TCID50 for the second injection. (Chen et al., 2005)
  • Immune Response: testing hosts generated high levels of neutralizing antibodies after 2 vaccinations
    (Chen et al., 2005)
  • Challenge Protocol: immunized on days 0 and 28 via intranasal injection before challenged after second immunization on day 28 with 105 TCID50 of pathogenic SATS-CoVPUMC01.
    (Chen et al., 2005)
  • Efficacy: likely protected (Chen et al., 2005)
  • Description: After virus challenge, SARS-CoV shedding detected by RT-PCR was only detected in the nasopharyngeal specimens of one of the four ADS-MVA immunized animals (Rh0413) on day 2 after virus challenge. No virus shedding was detectable on days 4 and 6 postchallenge in these four macaques. SARS-CoV could not be isolated from the lung specimens of ADS-MVA-immunized macaques on day 7 postchallenge. (Chen et al., 2005)
References
Chen et al., 2005: Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen KY, Ho DD. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. Journal of virology. 2005; 79(5); 2678-2688. [PubMed: 15708987].
Weingartl et al., 2004: Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, Smith G, Jones S, Proulx R, Deschambault Y, Grudeski E, Andonov A, He R, Li Y, Copps J, Grolla A, Dick D, Berry J, Ganske S, Manning L, Cao J. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. Journal of virology. 2004; 78(22); 12672-12676. [PubMed: 15507655].